Medicare AdvantageCoverageMedium impact
MA11.014h, Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toe Nails
Independence Blue Cross·Podiatry, Dermatology·Medical Policy
Effective date
Oct 1, 2025
We identified it
Jun 19, 2026
Summary
Policy MA11.014h establishes coverage guidelines for debridement of mycotic (fungal) and symptomatic non-mycotic hypertrophic toenails effective October 1, 2025. This recent policy requires billing teams to verify coverage criteria, medical necessity documentation, and applicable authorization requirements before submitting claims for these procedures.
Action Required
By September 30, 2025: Billing team must obtain and review the full policy text from the provided URL to extract specific CPT/HCPCS codes, prior authorization requirements, and medical necessity criteria. Update billing software with any new authorization rules or code restrictions. Providers must document medical necessity (mycotic infection diagnosis or symptomatic non-mycotic hypertrophy) on all claims. Front desk staff should flag toenail debridement cases for verification before scheduling. Failure to follow coverage criteria will result in claim denials.